# High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis

> **NCT04521803** · PHASE2 · RECRUITING · sponsor: **University of Cape Town** · enrollment: 60 (estimated)

## Conditions studied

- Tuberculous Pericarditis
- HIV Status

## Interventions

- **DRUG:** high dose Rifampicin (RIF)

## Key facts

- **NCT ID:** NCT04521803
- **Lead sponsor:** University of Cape Town
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-10
- **Primary completion:** 2025-09-15
- **Final completion:** 2026-02-28
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04521803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04521803, "High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04521803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*